Issue 50

Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on DMT’s power to treat Major Depressive Disorder

Small Pharma recently completed a Phase I trial to treat Major Depressive Disorder with proprietary DMT formulation SPL026. The company will now move ahead with the first regulated clinical trial of DMT-assisted therapy in patients.

PSYCH spoke to Chief Medical and Scientific Officer, Carol Routledge, a drug development expert with over thirty years’ experience, on the treatment’s potential and the opportunities for investors.

ATAI CREATES SUBSIDIARY TO TARGET DEPRESSION WITH PRECISION PSYCHIATRY

The venture, with Chymia LLC, sees atai expand into precision psychiatry.

HOW COVID-19 OPENED THE DOOR TO A NEW ERA IN PSYCHEDELIC MEDICINE

TIME Magazine on the mental health crisis and psychedelics as medicine.

BUSINESS AND INVESTMENT

Tryp Therapeutics creates research partnership with University of Wisconsin-Madison.

Novamind launches palliative care programme.

Psyched starts pre-clinical trials with amanita muscaria-derivative AME-1.

Start-ups are betting on a psychedelic gold rush.

Numunis applies for research licence for new laboratory.

Mynd to sell biometric diagnostic tests through subsidiary Mynd Diagnostics.

Former Organigram CEO, Greg Engel, joins Clairvoyant Therapeutics.

Cybin files patents for drug delivery.

The Psychedelics as Medicine Report: Third Edition

The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.

Key findings:

The medical psychedelic market is valued at US$190 million, and is expected to exceed US$2.4 billion by 2026.
Investment in psychedelic companies has now surpassed US$2 billion.
Two-thirds of North Americans and Europeans support the legalisation of psychedelic-assisted therapy.

Download your complimentary copy

SCIENCE AND RESEARCH

Is mysticism becoming a problem for psychedelic medicine?

Exploring the combination of psychedelics and psychotherapy.

University of Wisconsin shares research update.

‘Homebrew’ psilocybin made using widely available materials.

Psychedelic use associated with lower odds of heart disease and diabetes.

REGULATION AND LEGISLATION

Denver to expand psilocybin decriminalisation to allow communal use.

A strategy for rescheduling psilocybin.

Arcata City Council effectively decriminalises psilocybin.